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Abstract
Background: Cancer, like other diseases accompanied by strong metabolic disorders, shows
characteristic effects on cell turnover rate, activity of modifying enzymes and DNA/RNA
modifications, resulting also in elevated amounts of excreted modified nucleosides. For a better
understanding of the impaired RNA metabolism in breast cancer cells, we screened these
metabolites in the cell culture supernatants of the breast cancer cell line MCF-7 and compared it
to the human mammary epithelial cells MCF-10A. The nucleosides were isolated and analyzed via
2D-chromatographic techniques: In the first dimension by cis-diol specific boronate affinity
extraction and subsequently by reversed phase chromatography coupled to an ion trap mass
spectrometer.
Results: Besides the determination of ribonucleosides, additional compounds with cis-diol
structure, deriving from cross-linked biochemical pathways, like purine-, histidine- and polyamine
metabolism were detected. In total, 36 metabolites were identified by comparison of fragmentation
patterns and retention time. Relation to the internal standard isoguanosine yielded normalized area
ratios for each identified compound and enabled a semi-quantitative metabolic signature of both
analyzed cell lines.
13 of the identified 26 modified ribonucleosides were elevated in the cell culture supernatants of
MCF-7 cells, with 5-methyluridine, N2,N2,7-trimethylguanosine, N6-methyl-N6-
threonylcarbamoyladenosine and 3-(3-aminocarboxypropyl)-uridine showing the most significant
differences. 1-ribosylimidazole-4-acetic acid, a histamine metabolite, was solely found in the
supernatants of MCF-10A cells, whereas 1-ribosyl-4-carboxamido-5-aminoimidazole and S-
adenosylmethionine occurred only in supernatants of MCF-7 cells.
Conclusion: The obtained results are discussed against the background of pathological changes in
cell metabolism, resulting in new perspectives for modified nucleosides and related metabolites as
possible biomedical markers for breast carcinoma in vivo.
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Since many of the presently applied biomedical markers
are not recommended for early diagnosis and therapy sur-
veillance of cancer (e.g. CA-15-3 and CEA in breast can-
cer) [1], an intensified search for more reliable diagnostic
markers is required.
Beside the clinical research for characteristic biomarkers
in the genomic profile (genomics) and the expressed pro-
tein pattern (proteomics), increasing interest is directed
towards the end products of physiological processes rep-
resented by different metabolite classes.
The field of metabolomics deals with the fingerprint anal-
ysis of biochemical alterations among various metabolic
degradation products initiated by diseases, drugs and tox-
ins in a defined biological system [2]. Many of the key
metabolic pathways are interconnected and thus pertur-
bations – for instance caused by malignant cancer diseases
– in one subset can cause implications on the others. The
metabolomic approach in conjunction with its practical
appliance for early diagnosis and therapy surveillance in
certain diseases is to narrow down the great diversity of
possible compounds to those with a huge information
content for classification predictions.
Possible targets for a characteristic metabolite fingerprint
associated with neoplastic cancer diseases are compounds
originating from the cellular RNA metabolism and
peripheral biochemical processes.
The cross-linked pathways of purine de novo biosynthesis
and histidine metabolism (Fig. 1A) contribute to the cel-
lular ribonucleotide pool and thus the general build up of
RNA molecules. The polyamine/methionine cycle is
directly connected to the enzymatic modification of RNA
nucleosides via the ubiquitous methyl- and propylamino-
donor S-adenosylmethionine (SAM) (Fig. 1B).
RNA contains a series of modified nucleosides in addition
to the common ribonucleosides adenosine (A), guanos-
ine (G), uridine (U) and cytidine (C). Modifications like
methylation, hydroxylation, reduction, isomerization,
sulfur/oxygen substitution and addition of complex side
chains are implemented posttranscriptionally within the
polynucleotide molecule by various modifying enzyme
systems.
The major task of these modifications is thought to be the
general improvement of biological activity, integrity and
efficiency of RNA in various biochemical processes [3].
At present about 100 modified nucleoside structures are
known to occur in different RNA types like transfer RNA
(tRNA), messenger RNA (mRNA), ribosomal RNA (rRNA)
and small nuclear RNA (snRNA) with tRNA being the
most intensively modified (up to 25% in higher eukaryo-
tes) [4].
During posttranslational RNA catabolism, nucleosides are
released due to enzymatic hydrolysis of the polynucle-
otides and subsequent elimination of the phosphate moi-
ety. The common nucleosides C, U, A and G are recycled
for intracellular RNA-rebuilding in the so-called salvage
pathway by stepwise re-phosphorylation to the corre-
sponding triphosphate nucleotides.
This passage is obstructed for modified nucleosides due to
the lack of specific phosphorylases. Thus they are excreted
quantitatively out of the cell as metabolic end products
via blood stream into the urine [5].
In cancer, RNA metabolism is impaired, which has been
demonstrated by altered levels of modified nucleosides.
In this context, RNA metabolites have been analyzed in
several biological fluids like blood [6] and urine [7] as
well as in RNA-hydrolysates [8].
It was shown that the levels of 1-methylinosine (m1I) and
N2,N2-dimethylguanosine (m22G) are elevated in urine
from breast cancer patients [9]. Increased amounts of
modified nucleosides were also observed in urine of
patients suffering from leukemia [10], gastrointestinal
cancer [11] and lung carcinoma [12].
Different methods have been applied for identifying and
quantifying nucleosides using high-performance liquid
chromatography (HPLC) with UV detection and capillary
electrophoresis (CE) [13]. Recently, the coupling of
HPLC, gas chromatography or capillary liquid chromatog-
raphy with mass spectrometric detection via electrospray
ionization ion trap mass spectrometry (ESI-IT MS) [14],
ESI tandem MS [15] and fast atom bombardment (FAB
MS) [16] has been applied. ESI-TOF MS [17] and offline
mass spectrometric techniques like MALDI-TOF MS [18]
have proven valuable tools for the identification of nucle-
oside structures.
Bioinformatic methods like artificial neural network
(ANN) [19], principal component analysis (PCA) [20],
learning vector quantization (LVQ) and support vector
machine (SVM) [21] enabled sophisticated nucleoside
pattern recognitions, resulting in improved values for spe-
cificity/sensitivity and hence a more significant classifica-
tion in early cancer diagnosis.
Related to metabolic profiling in blood and urine, cell cul-
ture supernatants offer the great advantage of the exclu-
sion of subsequent interferences along the excretion
pathway, e.g. enzymatic actions in the blood stream, liverPage 2 of 14
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Cellular pathways interacting with RNA metabolismFigure 1
Cellular pathways interacting with RNA metabolism. A: purine de novo biosynthesis and histidine metabolism. Involved key 
enzymes: 1) 5'-nucleotidase (EC 3.1.3.5), 2) AICAR transformylase (EC 2.1.2.3), 3) adenylsuccinate synthetase (EC 6.3.4.4), 4) 
adenylsuccinate lyase (EC 4.3.2.2, catalyzes both conversion of succinyl-AMP into AMP and SAICAR (N-succinyl-5-amino-imi-
dazol-4-carboxamid-ribonucleotid into AICA ribotide), 5) histidine decarboxylase (EC 4.1.1.22), 6) phosphatases and 5'-nucle-
otidase, bold: analyzed metabolites; abbreviations: PRPP (5-phospho-ribosyl-1-pyrophosphate); for all other abbreviations, 
refer to text. B: polyamine/methionine cycle. Involved key enzymes: 1) S-adenosylmethionine decarboxylase (EC 4.1.1.50), 2) 
ornithine decarboxylase (EC 4.1.1.17), 3) propylaminotransferase 1 (EC 2.5.1.16), 4) propylaminotransferase 2 (EC 2.5.1.22), 5) 
oxygenases, 6) methylthioadenosine phosphorylase (EC 2.4.2.28), 7) DNA-(5-cytosine)-methyltransferase (EC 2.1.1.37), 8) 
tRNA-uridine aminocarboxypropyltransferase (EC 2.5.1.25),); bold: analyzed metabolites; abbreviations: put (putrescine), spd 
(spermidine), spm (spermine), dcSAM (decarboxylated SAM), MTR-1P (S-methyl-5'-thio-D-ribose-1-phosphate); for all other 
abbreviations, refer to text.
BMC Biochemistry 2007, 8:25 http://www.biomedcentral.com/1471-2091/8/25and kidney as well as the falsification by bacterial metab-
olites. Thus, it is possible to generate unaltered metabolite
patterns of cellular origin.
According to the metabolomic approach of contemplat-
ing the analyzed biological system as a whole set of more
or less interconnected processes, we screened cross-linked
metabolic pathways of the cellular RNA metabolism.
Therefore we performed a qualitative and semi-quantita-
tive LC-IT MS analysis of nucleosides and related metabo-
lites (Fig. 2) excreted by breast cancer cell cultures to get a
deeper insight into properties and variations of cell
metabolism at the point of origin.
Results and Discussion
In the present study, we utilized the potentials of ion trap
mass spectrometry to analyze differences in the metabo-
lite excretion patterns of MCF-7 breast cancer cell line and
MCF-10A breast epithelial cell line.
For compound identification we applied auto-LC-MS3
runs [14] of the extracted cell culture supernatant samples.
Collision induced dissociation (CID)-experiments ena-
bled the generation of constant neutral loss (CNL) chro-
matograms, showing only those compounds losing a
defined functional group in the first fragmentation step.
In nucleoside structures, this step is generally represented
by the characteristic decay into the neutral sugar moiety
and the corresponding nucleic base fragment at the fragile
N-glycosidic bond. Loss of 132 amu is a strong indication
for metabolites with an unaltered ribose, 116 amu loss
points at a 5'-deoxyribose decay (2'-and 3'-deoxyribose
moieties can be excluded due to the requirement of a cis-
diol structure for retention on the affinity chromatogra-
phy column). 5'-deoxy-5'-methylthioadenosine (MTA,
CNL: 162 amu), 5'-deoxy-5'-methylthioadenosine sulfox-
ide (MTA-SO, CNL: 178 amu), S-adenosylhomocysteine
(SAH, CNL: 249 amu) and SAM (CNL: 263 amu) elimi-
nate the corresponding thioribose derivatives. (Fig. 3).
Structures of some of the identified and analyzed metabolitesFigure 2
Structures of some of the identified and analyzed metabolites. Abbreviations: m2,2,7G (N2,N2,7-trimethylguanosine), 
m5U (5-methyluridine), m6t6A (N6-methyl-N6-threonylcarbamoyladenosine), MTA (5'-deoxy-5'-methylthio-adenosine), MTA-
SO (5'-deoxy-5'-methylthioadenosine sulfoxide), IAA-R (1-ribosylimidazole-4-acetic acid), SAM (S-adenosylmethionine), SAH 
(S-adenosylhomocysteine).Page 4 of 14
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ridine (Ψ) do not loose the entire sugar moiety in the first
fragmentation step but show multistep water elimina-
tions within the ribose structure.
The characteristic decay of the sugar moiety (ribose or
modified ribose) observed in the MS/MS step and the sub-
sequent fragmentation of the remaining heterocycle (e.g.
the corresponding nucleic base) by MS3 gave precious
information about the structural identity of the isolated
compounds (Fig. 4).
Constant neutral loss (CNL) chromatograms of a MCF-7 cell culture supernatant sampleFigure 3
Constant neutral loss (CNL) chromatograms of a MCF-7 cell culture supernatant sample. The different CNL amu 
values are characteristic for the various ribose structures of the analyzed metabolites, lost as a neutral moiety in the MS/MS 
fragmentation of the labile C-N-glycosidic bond between sugar and base. Numbers refer to metabolites listed in table 1. ψ (no 
characteristic neutral loss because of stable C-C-glycosidic bond) and IAA-R (not detectable in supernatants of MCF-7) are not 
shown.Page 5 of 14
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ferent metabolic cell pathways were identified by compar-
ison of fragmentation patterns and retention time to
analogous standards.
1-ribosylimidazole-4-acetic acid (IAA-R) and 3-(3-amino-
carboxypropyl)-uridine (acp3U) were previously identi-
fied by our research group in human urine with combined
LC-IT MS and ESI-TOF MS measurements [17]. 1-ribosyl-
pyridin-2-one-5-carboxamide (2,5-PCNR) was identified
by MALDI-TOF MS analysis [18].
1-ribosylnicotinamide (NA-R), 5-carbamoylmethylurid-
ine (ncm5U), MTA-SO, 5'-deoxyadenosine (5'-dA), N6-
methyl-N6-threonylcarbamoyladenosine (m6t6A), 
2-methylthio-N6-threonyl-carbamoyladenosine (ms2t6A)   
and 5-methoxycarbonyl-methyl-2-thiouridine 
(mcm5s2U) were identified in a parallel in-depth study of
urinary metabolites by accurate mass measurement via FT
MS combined with fragmentation pattern analysis by IT
MS (data not published yet, paper in preparation). As the
obtained fragmentation pathways and retention times of
the mentioned compounds are similar in both analyzed
biological fluids, they are most probably identical. An
assortment of MS3 fragmentation patterns for selected
metabolites is shown in Table 1.
For a comparative, semi-quantitative pattern analysis of
the two studied cell lines, the peak areas of the identified
metabolites in the processed EICs were related to the peak
area of the internal standard isoguanosine (Table 2).
Some of the analyzed metabolites show striking varieties
Fragmentation pathway proposal for the modified nucleoside N4-acetylcytidine (ac4C)igur  4
Fragmentation pathway proposal for the modified nucleoside N4-acetylcytidine (ac4C).Page 6 of 14
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presumably caused by the cellular response to pathophys-
iological mutations (Fig. 5).
Modified nucleosides
We found that the modified nucleosides 5,6-dihydrourid-
ine (DHU), Ψ, acp3U, 3-methylcytidine (m3C), 5-methyl-
uridine (m5U), 3-methyluridine (m3U), xanthosine (X),
1-methylguanosine (m1G), m22G, N2,N2,7-trimethylgua-
nosine (m2,2,7G), mcm5s2U, N6-threonylcarbamoylade-
nosine (t6A) and m6t6A are elevated in the supernatants of
MCF-7 cells compared to those of MCF-10A cells. There-
fore, we generally considered a compound level as "ele-
vated" when the area ratio exceeds the mean value of the
reference cell line by two standard deviation values (2σ-
concept) [5]. The methylated nucleoside N6-methylade-
nosine (m6A) is not included in this list because it can be
formed through isomerization of 1-methyladenosine
(m1A) and thus could not be normalized.
Especially the levels of m5U with ratios ~4/1 (MCF-7/
MCF-10A), m2,2,7G (~2:1), m6t6A (~2:1) and acp3U (~2:1)
should be pointed out.
m5U is present in eukaryotic tRNA and rRNA [22]. Roe
and Tsen postulated, that this nucleoside might be
involved in the regulation of translational processes in
mammalian liver [23]. Its formation in tRNA is associated
with the stabilization of the macromolecular structure. A
lack of m5U, 2'-O-methylguanosine and Ψ at the posi-
tions 54, 18 and 55 in tRNAs of Escherichia coli induced a
reduced growth rate and led to defects in translation proc-
esses [24].
m2,2,7G is present in eukaryotic mRNA and snRNA [22]. In
the latter, the hypermethylated guanosine is part of the
m3G-cap-structure, a snRNA-specific variant of the regular
monomethylguanosine-(m7G)-cap at the 5'-termini. Nas-
cent snRNAs (with m7G-cap) are transported to the cyto-
plasm were they assemble with small nuclear
ribonucleoprotein particles (snRNPs). Subsequently, the
two additional methyl groups are transferred from SAM
and the snRNA/protein-complex can enter the nucleus
[25].
Small nuclear RNAs belong to a group of non-coding
RNAs (ncRNAs). These RNA species have been implicated
in diseases including various cancers and neurological dis-
eases [26]. SnRNAs can suppress the expression of genes.
They probably bind directly to mRNAs and stop protein
production. Additionally snRNAs seem to regulate gene
expression epigenetically. The massive amount of ncRNA
that is expressed from the genomes of higher organisms
suggests that ncRNA may constitute an endogenous con-
trol system that regulates the programmed patterns of
gene expression [27]. Increased levels of m2,2,7G in MCF-
7 cells might indicate a "tumorigenic" change of gene
expression on the epigenetic level.
Table 1: IT MS3 fragmentation patterns of selected metabolites, occurring in the analyzed cell culture supernatants.
compound name MS MS2† MS3
1-ribosylimidazole-4-acetic acid 259 127 (MH+-R) 81 (127-HCOOH)
1-ribosylnicotinamide 255 123 (MH+-R) 106 (123-NH3)
96 (123-HCN)
80 (123-HNCO)
S-adenosylmethionine 399 136 (MH+-mR) 119 (136-NH3)
109 (136-HCN)
94 (136-NH2CN)
5-carbamoylmethyluridine 302 170 (MH+-R) 153 (170-NH3)
1-ribosyl-4-carboxamido-5-aminoimidazole 259 127 (MH+-R) 110 (127-NH3)
S-adenosylhomocysteine 385 136 (MH+-mR) 119(136-NH3)
109(136-HCN)
94 (136-NH2CN)
5'-deoxy-5'-methyl-thioadenosine sulfoxide 314 136 (MH+-mR) 119(136-NH3)
109(136-HCN)
94(136-NH2CN)
5'-deoxyadenosine 252 136 (MH+-mR) 119 (136-NH3)
109 (136-HCN)
94 (136-NH2CN)
5-methoxycarbonylmethyl-2-thiouridine 333 201 (MH+-R) 169 (201-CH3OH)
141 (201-CH3OCHO)
N6-methyl-N6-threonylcarbamoyladenosine 427 295 (MH+-R) 150 (295-C5H7NO4)
2-methylthio-N6-threonylcarbamoyladenosine 459 327 (MH+-R) 208 (327-C4H9NO3)
182 (327-C5H7NO4)
† R: loss of ribose (132 amu), mR: loss of modified ribosePage 7 of 14
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BMC Biochemistry 2007, 8:25 http://www.biomedcentral.com/1471-2091/8/25To date the occurrence of m6t6A has been described in
tRNAThr from E. coli, wheat embryo tRNA and rat liver
tRNASer [28]. The methyl group of this nucleoside is sup-
posed to improve the tRNA reading efficiency in E. coli
[29].
To the authors' best knowledge, this report describes for
the first time the identification of this hypermodified
nucleoside in human cell lines.
The nucleoside acp3U occurs in several mammalian
tRNAs [30]. It is posttranscriptionally synthesized via
transfer of the aminocarboxypropyl moiety of SAM on
certain uridine residues in the RNA macromolecule, yield-
ing MTA as degradation product [31] (Fig. 1B). An ele-
vated production of acp3U is thus directly associated with
an elevated build up of MTA as observed in MCF-7 cells
(see section "MTA and polyamine biosynthesis").
Randerath et al generally proposed that the reason for dif-
ferences in the base composition of tumor tRNA and thus
the excreted modified nucleosides may be changes in the
concentrations of specific tRNAs, presence of tRNAs with
altered sequences in tumor tissue and aberrant modifica-
tions [32].
The methylated nucleosides are synthesized at the post-
transcriptional level by transfer of methyl groups from
SAM to the nucleobase at certain positions in the RNA
molecule by specific enzyme systems. The observed
Table 2: Metabolite excretion in cell culture supernatants of MCF-10A cells and MCF-7 breast cancer cells.
No. compound name M+H+ MCF-10A MCF-7
AreaQ *1000† mean (n = 3) ± SD AreaQ *1000 mean (n = 3) ± SD
1 1-ribosylimidazole-4-acetic acid 259 19.83 ± 1.07 n.d.
2 Dihydrouridine 247 210.30 ± 19.13 261.58 ± 14.58
3 Pseudouridine 245 513.38 ± 26.77 658.02 ± 30.67
4 1-ribosylnicotinamide 255 1985.96 ± 206.67 729.10 ± 43.95
5 Cytidine 244 2044.16 ± 190.68 1066.82 ± 86.71
6 S-adenosylmethionine 399 n.d. 335.55 ± 21.75
7 5-carbamoylmethyluridine 302 32.47 ± 0.73 18.10 ± 0.96
8 3-(3-aminocarboxypropyl)-uridine 346 7.13 ± 0.63 12.89 ± 0.60
9 Uridine 245 1103.56 ± 30.38 504.13 ± 80.28
10 3-methylcytidine 258 382.01 ± 9.65 458.36 ± 16.08
11 1-ribosyl-4-carboxamido-5-aminoimidazole 259 n.d. 251.47 ± 22.35
12 1-methyladenosine 282 2170.75 ± 104.62 2067.45 ± 67.84
13 5-methylcytidine 258 437.16 ± 25.90 446.30 ± 14.00
14 Inosine 269 147.28 ± 9.77 46.89 ± 10.41
15 5-methyluridine 259 35.90 ± 1.48 141.70 ± 4.01
16 Guanosine 284 79.84 ± 8.73 15.31 ± 3.02
17 1-ribosyl-pyridin-2-one-5-carboxamide 271 56.25 ± 27.64 46.70 ± 4.94
18 3-methyluridine 259 20.30 ± 1.25 26.91 ± 0.59
19 Xanthosine 285 13.10 ± 0.27 18.96 ± 1.84
20 S-adenosylhomocysteine 385 7.53 ± 0.43 47.77 ± 0.98
21 1-methylinosine 283 282.12 ± 32.66 269.92 ± 6.25
22 1-methylguanosine 298 648.74 ± 5.15 700.59 ± 10.64
23 5'-deoxy-5'-methyl-thioadenosine sulfoxide 314 23.73 ± 0.95 32.40 ± 6.31
24 N4-acetylcytidine 286 296.08 ± 4.84 298.65 ± 6.69
25 N2-methylguanosine 298 293.26 ± 14.32 206.55 ± 7.32
26 Adenosine 268 5.97 ± 0.10 32.57 ± 7.16
27 N6-succinyloadenosine 384 130.04 ± 2.59 97.78 ± 3.40
28 N2,N2-dimethylguanosine 312 460.45 ± 19.86 587.62 ± 9.99
29 N2,N2,7-trimethylguanosine 326 129.55 ± 7.07 263.28 ± 5.54
30 5'-deoxyadenosine 252 101.50 ± 16.49 81.81 ± 2.47
31 5-methoxycarbonylmethyl-2-thiouridine 333 10.55 ± 0.23 12.60 ± 0.34
32 N6-methyladenosine 282 22.97 ± 11.04 32.67 ± 12.12
33 N6-threonylcarbamoyladenosine 413 42.34 ± 1.83 67.25 ± 0.44
34 5'-deoxy-5'-methyl-thioadenosine 298 3452.12 ± 213.17 5668.00 ± 125.15
35 N6-methyl-N6-threonylcarbamoyladenosine 427 3.11 ± 0.04 5.96 ± 0.46
36 2-methylthio-N6-threonylcarbamoyladenosine 459 3.68 ± 0.15 3.47 ± 0.16
† AreaQ* 1000 = (peak area [M+H+ + M+Na+ + M+K+] (analyt)/peak area [M+H+ + M+Na+ + M+K+] (internal standard isoguanosine)) * 1000 
(factor), tabulated by increasing retention time, n.d.: not detectablePage 8 of 14
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BMC Biochemistry 2007, 8:25 http://www.biomedcentral.com/1471-2091/8/25increased excretion of certain methylated nucleosides can
be generally traced back to the elevated activity of specific
tRNA methylases associated with breast carcinoma [33].
Beside its main task in translational processes, additional
functions of tRNA, e.g. the participation as cofactor in
enzymatic reactions, have been reported. In this context,
tRNA modifications or tRNA modifying enzymes are
thought to act as regulatory devices between the transla-
tional and other metabolic processes. The degree of mod-
ification in the individual tRNA species is regulated
differently under the influence of the physiological status
of the cell (e.g. the growth rate) [34]. Thus, the observed,
elevated excretion of certain modified nucleosides may be
attributed to the tumor growth's induced accumulation of
specific tRNAs with characteristic nucleoside composi-
tion.
The excretion of the common ribonucleosides also shows
striking differences between the analyzed cell lines: G,
ratio ~1:5 (MCF-7/MCF-10A), U (~1:2), C (~1:2) and A
(~5:1). In the latter case, the possible action of adenosine
desaminase, converting adenosine to inosine (I) has to be
considered (ratio of I: (~1:3)). The phenomenon of a
reduced excretion of common nucleosides in MCF-7
might be related to the increased cell turnover and thus
RNA metabolism reported in tumor tissue [35] with a
higher demand for nucleoside recycling.
S-adenosylmethionine, S-adenosylhomocysteine
The elevated activity of methylases in malignant cancer
diseases has to be estimated in conjunction with the ubiq-
uitous methyldonor SAM and the related metabolic com-
pounds (Fig. 1B).
SAM was solely found in the supernatants of MCF-7
whereas it was not detectable in MCF-10A. Elevated excre-
tion has been observed in cells showing methionine
dependent growth [36], like MCF-7.
SAH is the degradation product of SAM when acting as
methyldonor in most of the enzymatically induced
methyl-transfer reactions, e.g. the methylation of RNA-
nucleosides. The inhibitory effect of SAH on methylation
reactions is well-documented [37] and explains the ele-
vated level in the cell culture supernatants of MCF-7.
As normally the enzyme systems involved in this pathway
are strictly regulated, a severe change in the cell physiol-
ogy like cancer may lead to an overproduction of SAM for
transmethylation and thus to an elevated excretion of
SAM and SAH out of the cell.
MTA and polyamine biosynthesis
MTA and its oxidized metabolite MTA-SO are elevated in
the supernatants of MCF-7 cells.
MTA is not a nucleoside derived from RNA but a byprod-
uct in the polyamine biosynthesis. It is generated via
transfer of the propylamino moiety from decarboxylated
S-adenosylmethionine (dcSAM) on the polyamine-com-
pounds putrescine and spermidine (Fig. 1B). MTA-SO is
suggested to arise from MTA by in vivo oxidation with per-
oxides and superoxides or enzymatically by microsomes
[38]. Separate studies in our research group confirmed the
enzymatically induced oxidation of MTA, yielding MTA-
SO by incubation of MTA with rat liver microsomes (data
not published). Thus the elevated excretion of MTA-SO in
MCF-7 appears to be simply in consequence to the higher
MTA level.
Polyamines are regulatory compounds in cell growth
processes. Individuals with malignant cancer diseases
show elevated amounts of polyamines in physiological
fluids [39]. Levels of the enzymes involved in the
polyamine biosynthesis (ornithine decarboxylase and S-
adenosylmethionine decarboxylase) are higher in tumors
than in normal tissue [40]. Thus the polyamine biosyn-
thesis pathway is discussed as useful target for anticancer
therapeutics since depletion in polyamine levels has been
shown to inhibit cellular growth [41].
Characteristic differences in the metabolite excretion of MCF-10A (A) and MCF-7 (B) c ll culture superna antsFigure 5
Characteristic differences in the metabolite excre-
tion of MCF-10A (A) and MCF-7 (B) cell culture 
supernatants. Comparison of the Extracted Ion Chromato-
gram traces (EIC) 259 (M+H+) + 281 (M+Na+) + 297 
(M+K+) of the corresponding metabolites IAA-R, AICA ribo-
side and m5U from LC-IT MS analysis of cell culture superna-
tants of mammary epithelial cells MCF-10A and breast cancer 
cell line MCF-7.Page 9 of 14
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BMC Biochemistry 2007, 8:25 http://www.biomedcentral.com/1471-2091/8/25The higher excreted level of MTA may be interpreted as a
consequence to an elevated polyamine biosynthesis pro-
ceeding in rapidly proliferating tumor cells. In human
leukemic cells, the relation between the up-regulated syn-
thesis of spermidine and spermine and excretion of MTA
has been well-documented [42]. To elucidate this process
in MCF-7 cells, the analysis of both intra-and extracellular
polyamine levels as well as the determination of the key
enzyme activities has to be performed in further experi-
ments.
Another focus is directed towards the metabolic fate of
MTA, which is degraded to adenine and S-methyl-5'-thio-
D-ribose-1-phosphate (MTR-1P) by the enzyme MTAP
(Fig. 1B). In some breast cancer cell lines, including MCF-
7, the MTAP gene is inactive [43]. The elevated MTA level
in the supernatant of MCF-7 compared to the supernatant
of MCF-10A may be explained by this phenomenon,
because MTA may not be degraded.
Accumulating MTA is known for its inhibitory effect on
polyamine aminopropyltransferase, methyltransferases
[44] and cell growth in general [45] – processes important
for the growth and development of cancer cells. Thus, the
elevated excretion of MTA in MCF-7 may be related to
these attributes.
Furthermore, it may be assumed that in case of an inactive
MTAP, the methionine synthesis mainly takes place via
the recycling pathway. The first step in this cycle is
demethylation of SAM to SAH. The elevated levels of both
compounds found in the supernatants of MCF-7 support
this presumption. The methylation of RNA nucleosides
also depends on this cycle, so the increased excretion of
methylated nucleosides in the analyzed cell culture super-
natants may also be related to the described gene defect.
Histidine metabolism and purine de novo biosynthesis
A significant difference was observed in the excretion of 1-
ribosyl-4-carboxamido-5-aminoimidazole (AICA ribo-
side), the dephosphorylated analog of AICA ribotide
(AICAR), which is a crosslinked intermediate in purine de
novo biosynthesis/histidine metabolism and a precursor
of AMP (Fig. 1A).
Whereas AICA riboside was found in the supernatants of
MCF-7, it is absent in those of MCF-10A.
A characteristic of tumor cells is the high rate of anabolic
processes like lipid-, protein- and DNA biosynthesis.
These energy-consuming pathways are regulated by the
energy status of the cell, based on the intracellular ATP/
AMP ratio. Swinnen et al demonstrated the response of
exogenously added AICAR riboside on invasive MDA-MB-
231 cells, a well-characterized model of breast cancer.
AICA riboside was taken up by the tumor cells and con-
verted to AICAR. This resulted in a distinctive inhibition
of tumor-associated anabolic processes, cell proliferation
and colony formation as well as an activation of AMP-acti-
vated protein kinases (AMPK). At high concentrations
applied, apoptosis was induced [46]. AMPKs in term are
suggested to be involved in the apoptosis process of cells.
An activation as well as a protection against apoptosis has
been reported, dependent upon the cell type [47]. It is not
known how AMPKs are involved in this process in MCF-7
cells.
However, it may be assumed that tumor cells like MCF-7
excrete endogenous AICAR as its cell permeable analog
AICA riboside to avoid the described inhibitory effects on
tumor growth and development.
Differences were also observed in the histidine metabo-
lism of the analyzed cell culture supernatants. The histi-
dine metabolite IAA-R is present in MCF-10A
supernatants but not detectable in those of MCF-7.
There is evidence suggesting that histamine, the precursor
molecule of IAA-R, is of major importance in the develop-
ment of malignant cancer. An increased enzymatic activity
of histidine decarboxylase has been observed in mam-
mary tumor tissue [48]. Functional histamine receptors
have been demonstrated in tumor cell lines [49]. Specific
inhibitors of the histamine-synthesizing enzyme, histi-
dine decarboxylase, have been shown to inhibit tumor
growth in different animal models [50], and in vitro [51],
suggesting that de novo synthesized histamine stimulates
tumor growth. An elevated biosynthesis of nascent,
tumor-associated histamine is thought to be involved in
the maintenance of a maximal growth and proliferation
rate by unknown intracellular targets. The mimicking of
the polyamine compounds putrescine and spermidine is
discussed in this context.
High levels of nascent histamine have also been discussed
in relation to a possible stabilization of condensed poly-
nucleotide species, formation of nucleic acid – protein –
polyamine complexes, control of aminoacyl tRNA and
protein synthesis [52].
Reynolds et al suggested that the high histamine concen-
tration in breast tumors supports the hypothesis that his-
tamine has immunosuppressive effects [53].
The fact that the histamine metabolite IAA-R was solely
found in cell culture supernatants of mammary epithelial
cells MCF-10A supports the assumption, that the newly
synthesized, nascent histamine in MCF-7 is needed for
certain processes in the tumor development and thus is
not further metabolized in the analyzed tumor cell line.Page 10 of 14
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In the present study, we applied LC-IT MS analysis as a
valid tool for biochemical investigations of altered meta-
bolic pathways in breast cancer cell lines. To the authors'
best knowledge, this is the first time that patterns of mod-
ified nucleosides and related, ribosyl-conjugated metabo-
lites were analyzed in cell culture supernatants of MCF-7
and MCF-10A cells, both well-defined models in malig-
nant and healthy mammary cells, respectively. We
observed remarkable differences in the compared meta-
bolic signatures, concerning modified nucleosides,
metabolites deriving from the polyamine/methionine
cycle as well as compounds from the purine de novo bio-
synthesis and the histidine metabolism. The discussed
metabolic pathways are all involved in the development
of malignant cancer diseases.
The obtained data justify a more detailed investigation of
metabolic profiles as possible tool to improve prognosis
and prediction in diseases like breast cancer. As they are
indicators for a changed phenotype in diseased cells,
metabolite patterns in body fluids like urine and blood
will influence future studies towards a potential non-inva-
sive diagnostic system in early breast cancer.
Methods
Cell culture
Breast cancer cell lines were purchased from the American
Type Culture Collection (ATCC, Manassas (VA), USA) and
cultivation was performed using the recommended
media. MCF-7 breast cancer cells (ATCC: HTB-22) were
grown in RPMI 1640 basal medium (Biochrome, Berlin,
Germany)/10% fetal calf serum (FCS; Biochrome)/1%
Penicillin-Streptomycin (Biochrome)/HEPES (Invitrogen,
Karlsruhe, Germany). MCF-10A breast epithelial cells
(ATCC: CRL-10317) were cultivated in Mammary Epithe-
lial Cell Basal Medium (Promocell, Heidelberg, Ger-
many)/Supplement Pack Mammary Epithelial Cell
Growth Medium containing bovine pituitary extract,
human epidermal growth factor (EGF; recombinant),
bovine insulin, and hydrocortisone (Promocell)/-1%
Penicillin-Streptomycin (Biochrome)/Choleratoxin (List
Biological Laboratories, Campbell, CA, USA).
In detail, 1 × 106 cells each were seeded in four plastic
flasks and grown in complete medium at 37°C/5% CO2
for four days. Then the number of cells was determined by
trypsinizing the cells in one flask and counting the viable
cells using a counting chamber. In the other three flasks
medium was changed to basal medium without additives
or fetal calf serum (FCS contains nucleosides itself and
would thus lead to false results). After four days of culture
the supernatant was collected and cleared from cell debris
by applying centrifugal force at 3000 rpm for 10 min. The
cleared supernatant was frozen at -20°C until further
analysis. The averaged number of cells was equal in both
MCF-10A and MCF-7 samples and enabled the direct
semi-quantitative comparison of the two analyzed cell
lines.
MCF-7 cell line
The MCF-7 cell line is the most widely used and best char-
acterized of all the human breast cancer cell lines. MCF-7
was isolated from the pleural effusion of a postmenopau-
sal 69 years adult Caucasian woman. The patient had
received radiotherapy and endocrine therapy before the
appearance of effusion [54]. The estradiol-dependence for
growth, antiestrogen sensitivity, and low metastatic
potential of MCF-7 cells has led to the hypothesis that
they represent an early epithelial adenocarcinoma of the
breast [55]. The MCF-7 line retains several characteristics
of differentiated mammary epithelium including the abil-
ity to process estradiol via cytoplasmic estrogen receptors
ER) and the capability of forming domes. Its hormone
receptor status is ERα-, ERβ- and progesterone receptor
(PR)-positive. MCF-7 cells are an excellent model in
which to study the process of malignant progression,
because they can be subjected to appropriate endocrino-
logic and physiologic selective pressures for the derivation
of variants with more progressed phenotypes. For exam-
ple, variants have been selected for antiestrogen resist-
ance. MCF-7 cells lack methylthioadenosine
phosphorylase (MTAP) activity, the key enzyme in the
methionine salvage pathway [56].
MCF-10A cell line
Soule et al have described a spontaneously immortalized
"normal" human breast epithelial cell line (MCF-10) [57].
These cells were isolated from mastectomy tissue obtained
from a premenopausal 36 years old Caucasian patient
with fibrocystic disease. After 849 days in culture, a popu-
lation designated MCF-10A was established. The MCF-
10A cells resemble luminal epithelial cells rather than
myoepithelial cells, and express antigens for several kerat-
ins and epithelial sialomucins [58]. The cells are nontum-
origenic in nude mice and do not exhibit anchorage-
independent growth. Thus far, the cells have shown no
signs of terminal differentiation or senescence. The line is
responsive to insulin, glucocorticoids, cholera endotoxin
and EGF. Its hormone receptor status is ERα- and PR neg-
ative.
Chemicals
We used methanol LiChroSolv, hypergrade, purchased
from Merck/VWR (Darmstadt, Germany) for liquid chro-
matography. Water was taken from an in-house double
distillation system. All other chemicals used were of ana-
lytical grade.Page 11 of 14
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compound identification in cell culture supernatants were
DHU, Ψ, C, U, A, m1A, m6A, I, m1I, G, m3C, 5-methylcy-
tidine (m5C), m1G, N2-methylguanosine (m2G), m22G,
m3U, m5U, X, N4-acetylcytidine (ac4C), t6A, m2,2,7G, MTA,
AICA riboside, SAM, SAH, nicotinamide (base standard
for MS3 fragmentation comparison with NA-R), imida-
zole-4-acetic acid (sodium salt, base standard for MS3 frag-
mentation comparison with IAA-R) and adenylosuccinic
acid (sodium salt, base standard for MS3 fragmentation
comparison with N6-succinyloadenosine (N6-SAR).
All standards were from Sigma (Taufkirchen, Germany)
except m22G, m2,2,7G and t6A which were obtained from
Biolog (Bremen, Germany). The internal standard isogua-
nosine was kindly donated by Prof. J.H. Kim of Seoul Uni-
versity, South Korea.
Affigel boronate was purchased from Biorad (Richmond,
USA).
Extraction of nucleosides and structurally related 
compounds from cell culture supernatants
Previous to the HPLC separation, the metabolites were
isolated from cell culture supernatants by cis-diol specific
affinity chromatography using phenylboronic acid gel.
This method was developed by Liebich et al in 1997 [59].
10 ml of cell culture supernatants were spiked with 100 µl
of internal standard solution (0.25 mM isoguanosine),
alkanalized to pH 8.8 with 2,5% ammonia solution and
then put on the column (500 mg Affigel boronate, col-
umn dimensions: 150 × 15 mm). Nucleosides and struc-
turally related compounds are bound reversibly and
specifically at the cis-diol group contained in the ribose
structure. After washing with 25 mL ammonium acetate
solution (0.25 mM, pH 8.8) and 6 ml methanol/water
(1:1, v/v), elution was carried out with 50 mL 0.2 M for-
mic acid in methanol/water (1:1, v/v). The solvent was
removed using a rotary evaporator and the nucleosides
were dissolved again in 0.5 ml ammonium formate solu-
tion (5 mM, pH 5). 10 µL of the residues were injected
into the HPLC-MS system.
Instrumentation
The chromatographic separation of the nucleosides was
performed on an Agilent 1100 Series HPLC system (Agi-
lent, Waldbronn, Germany) consisting of a Solvent
Degasser (G 1379 A), a binary capillary pump (G 1389),
an autosampler (G 1313 A), a column oven (G 1316 A)
and a DAD (G 1315 B). The chromatographic system con-
sisted of a Merck LiChroCART Superspher 100 RP-18 end-
capped column (125 × 2.0 mm i.d., 4 µm (Merck,
Darmstadt, Germany)) and a solvent gradient of 5 mM
ammonium formate buffer, pH 5.0, and methanol/water
(3:2, v/v)+0.1% formic acid. The column was operated at
25°C. The flow rate was set to 125 µl/min using a gradient
as described by Kammerer et al.[14].
The LC system was coupled to an Ion Trap mass spectrom-
eter. We used a Bruker Esquire HCT-Ion Trap (Bruker Dal-
tonics, Bremen, Germany) equipped with an ESI source in
positive ion mode for detection.
The capillary voltage was set to 4 kV, the dry temperature
in the electrospray source was 350°C, the nebulizer gas
was set to 45 psi and the dry gas to 9.0 l/min. The data
were acquired in standard enhanced scan mode (8,100 m/
z per second) in a mass range of 200–600 Da.
We performed auto LC-MS3 runs for compound identifi-
cation by fragmentation pathway and retention time and
a LC-MS method without fragmentation processes for
semi-quantitative metabolite pattern analysis.
In the latter case, Extracted Ion Chromatograms (EIC)
were generated by addition of [M+H+], [M+Na+] and
[M+K+] traces to normalize fluctuating alkali-contamina-
tion in the samples and the LC-MS system in the course of
analysis.
Data were acquired by Bruker EsquireControl version 5.1.
For post processing, Bruker DataAnalysis version 3.1 was
used.
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